Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/38VPpBl
via IFTTT